Norgen Biotek Corp., an innovative privately held Canadian biotechnology company, announced the launch of over 15 novel kits for the fast and simple isolation of nucleic acids (NA) from blood, plasma/serum and urine, including cell-free-circulating (cfc)RNA, cfcDNA and sequential cfcDNA and cfcRNA.

Data from comparisons of these kits with similar kits on the market clearly indicates that Norgen's kits yield significantly more diverse cfcRNA, owing to the fact that Norgen's kits use a proprietary resin technology that has the ability to bind all RNA sequences irrespective of size or GC content. The sensitivity and speed of these novel kits make them very powerful tools for a number of applications including the sensitive detection of tumour biomarkers and viruses, microRNA detection by PCR, quantitative PCR, RT-PCR, microarrays, Next Gen Sequencing, etc.

Norgen's blood/plasma/serum and urine kits utilise a convenient spin column format for NA purification from both fresh and frozen samples. In particular, the circulating NA kits provide a major advantage over other available kits in that they isolate significantly more diverse, inhibitor-free cfcRNA than any other technology on the market. Circulating NA present in 10 µL to 10 ml plasma inputs or 250 µL to 30 ml of urine inputs are concentrated into final elution volumes of 50 - 100 µL that can be used directly in sensitive downstream applications, as the kits completely remove all contaminants and inhibitors.

"These new kits represent a very exciting addition to our line of high quality products. These kits capture significantly more diverse cfcRNA (microRNA) from a given specimen than any other kit on the market, and therefore these kits are a must for scientists who diligently screen plasma yet are missing a significant number of targets. Re-examination of these specimens with our novel kits would allow detection of all those microRNAs that were previously missed. We also offer contract R&D to re-isolate cfcRNA and cfcDNA from these same specimens. Our mission is to accelerate discovery by bringing to market innovative Best-in-Class sample preparation products that can be used in research as well as in MDx applications." said Dr. Haj-Ahmad, president & CEO of Norgen Biotek.